Diabetes News and Research

Latest Diabetes News and Research

Gamma Pharmaceuticals inks brokerage agreement with J&A Lazier Racing

Gamma Pharmaceuticals Inc. announced it has signed a Product Brokerage Agreement with J&A Lazier Racing LLC of California. Mr. Lazier, an accomplished Indy Car Driver, will benefit from Gamma's Professional Grade vitamin supplements, nutritional and energy products to ensure peak athletic performance during the demanding Indy Car season.

28 Oct 2009

PureWellness announces enhancements to the PureWellness platform

PureWellness, Inc., a leading provider of online wellness solutions, announced the release of fourteen product additions and enhancements to the PureWellness platform.

28 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

Diabetes alerts for seniors from Always Best Care Senior Services

November is National Diabetes Month. And, Michael Newman, president of Always Best Care Senior Services, wants to alert seniors about the risks they face with this insidious disease.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Critical illness insurance, an additional layer of financial protection

As breast cancer awareness month winds to a close and pink ribbons symbolizing the brave fight against this disease take their place on survivors' dressers, the fight continues. Putting the spotlight on this devastating disease has made people think about their own mortality and what would happen if they were diagnosed with a critical illness, says Frank N. Darras, America's top Long Term Disability Lawyer.

28 Oct 2009

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

28 Oct 2009

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate, a beta-blocker medication taken by over half a million Americans for the treatment of high blood pressure, TOPROL-XL and its authorized generic, metoprolol succinate extended-release tablets are available.

28 Oct 2009

Liberator Medical Holdings announces record revenues for its fourth quarter of 2009

Liberator Medical Holdings, Inc. today pre-announces record net revenues of approximately $7.7 million for its fiscal fourth quarter ended September 30, 2009, representing an annualized revenue run rate of over $30.0 million.

28 Oct 2009

New biotechnology research center launched by SHRO

The Sbarro Health Research Organization (SHRO), a nonprofit research facility located at Temple University, will dedicate a new state-of-the-art biotechnology research center on Tuesday, October 27th, at 2 p.m. SHRO is one of the top three international laboratories, based on number of publications as ranked by the Cell Cycle Registry,

28 Oct 2009

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Orexigen® Therapeutics, Inc. today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy.

28 Oct 2009

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Arena Pharmaceuticals, Inc. reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate improvements in patients' body composition, cardiovascular risk factors and quality of life. These findings add to the previously announced top-line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in 4,008 patients.

28 Oct 2009

Go Daddy is the title sponsor of JDRF "Walk to Cure Diabetes"

For the third consecutive year, Go Daddy is the title sponsor of the Juvenile Diabetes Research Foundation International (JDRF) Walk to Cure Diabetes. The JDRF walk is this Saturday at Tempe Town Lake.

28 Oct 2009

The Endocrine Society urges NIH to increase funding for stem cell research

Stem cell research holds great promise for the treatment of millions of Americans with debilitating and possibly fatal diseases. Current legislation and guidelines, however, continue to limit researchers' endeavors in unlocking the potential breakthroughs that stem cell research can provide. To address this concern, today The Endocrine Society issued a Position Statement (http://www.endo-society.org/advocacy/policy) calling for an increase in NIH funding for stem cell research as well as expanding the scope of funding to include promising yet neglected areas of stem cell research.

28 Oct 2009

National Institutes of Health awards $735,000 grant for prenatal obesity and diabetes research

The National Institutes of Health has awarded Clemson University professor Maria Mayorga and Medical University of South Carolina professor Kelly Hunt a $735,000 grant to study the effects of a mother's obesity and diabetes on infant health in certain ethnic groups.

28 Oct 2009

DiabetEZE, an energy bar designed and developed for diabetics launched

Innova Nutrition announced today the launch of "DiabetEZE," an energy bar designed and developed for diabetics, but great for everyone.

28 Oct 2009

Vegetable intake during pregnancy can protect unborn child against diabetes

New evidence is emerging for how important it is for pregnant women to eat good, nutritious food. Expecting mothers who eat vegetables every day seem to have children who are less likely to develop type 1 diabetes, is revealed in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

28 Oct 2009

Mirafit fbcx reduces human body absorption of consumed fat

A scientific study to be presented today at the annual meeting of The Obesity Society will confirm significant weight loss using the pill mirafit fbcx®. Dr. K-L Catherine Jen and Dr. Joseph Artiss, principals at ArtJen Complexus USA, LLC, will present these clinical study findings today, October 27, at The Obesity Society 2009 annual scientific meeting at the Marriott Wardman Park Hotel in Washington, D.C., The Obesity Society's 27th annual scientific meeting.

28 Oct 2009

Internet-based diet and exercise program shows promise in lowering healthcare costs

Researchers from Boston University School of Medicine (BUSM) and Boston University School of Public Health (BUSPH) have shown that an employer-sponsored, internet-based diet and exercise program shows promise as a low-cost benefit to lower healthcare costs for those at higher risk for above-average costs and healthcare utilization such as cardiac, hyperlipidemia, hypertension or diabetes patients.

28 Oct 2009

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Prozac works wonders for some depressed people, but not for others. In some cases, patients derive little benefit and at worst, it can lead to bizarre hallucinations and fits of rage. Researchers and doctors remain puzzled as to what causes the wide range of reaction to Prozac and similar antidepressants.

28 Oct 2009

Diabetes News and Research

Latest Diabetes News and Research

Gamma Pharmaceuticals inks brokerage agreement with J&A Lazier Racing

PureWellness announces enhancements to the PureWellness platform

New CCS guidelines and position papers for physicians and nurse practitioners

Diabetes alerts for seniors from Always Best Care Senior Services

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

Critical illness insurance, an additional layer of financial protection

Folate-enriched prescription medical food lowers medical costs of patients with peripheral neuropathy

TOPROL-XL and metoprolol succinate are available for patients in all regions across the country: AstraZeneca

Liberator Medical Holdings announces record revenues for its fourth quarter of 2009

New biotechnology research center launched by SHRO

Orexigen Therapeutics presents phase 3 trial results of Contrave for treating obesity

Arena Pharmaceuticals presents data from its Phase 3 trial of LOrcaserin

Go Daddy is the title sponsor of JDRF "Walk to Cure Diabetes"

The Endocrine Society urges NIH to increase funding for stem cell research

National Institutes of Health awards $735,000 grant for prenatal obesity and diabetes research

DiabetEZE, an energy bar designed and developed for diabetics launched

Vegetable intake during pregnancy can protect unborn child against diabetes

Mirafit fbcx reduces human body absorption of consumed fat

Internet-based diet and exercise program shows promise in lowering healthcare costs

Scientists explore genetic 'Prozac markers'; research may provide simple test for treating depression

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Diabetes News and Research

Latest Diabetes News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in